A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia-Reference-Cited by-同舟云学术

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Published:2022-07-20 Issue:14 Volume:6 Page:4224-4227
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Broccoli Alessandro¹²^ORCID,Argnani Lisa²,Cross Matthew³^ORCID,Janus Agnieszka⁴,Maitre Elsa⁵^ORCID,Troussard Xavier⁵,Robak Tadeusz⁴^ORCID,Dearden Claire³,Else Monica⁶,Catovsky Daniel⁶^ORCID,Zinzani Pier Luigi¹²^ORCID

Affiliation:

1. 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna, Italy;

2. 2Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy;

3. 3Department of Haemato-Oncology, The Royal Marsden Hospital, London, United Kingdom;

4. 4Department of Hematology, Medical University of Lodz, Lodz, Poland;

5. 5Department of Hematology, CHU Caen Normandie, Caen, France; and

6. 6Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom

Abstract

Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/14/4224/1909774/advancesadv2022007854.pdf

Reference17 articles.

1. Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment;Troussard;Am J Hematol.,2022

2. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine;Goodman;J Clin Oncol.,2003

3. Response to therapy in hairy cell leukemia: systematic review and meta-analysis;Andrasiak;Clin Lymphoma Myeloma Leuk.,2018

4. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens;Noel;Leuk Lymphoma.,2011

5. Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia;Broccoli;Hematol Oncol.,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia;Leukemia & Lymphoma;2024-05-15

2. Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review;Cancers;2024-04-11

3. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

4. Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia;Blood Advances;2023-11-03

5. Subcutaneous and Intravenous Cladribine Treatment of Hairy Cell Leukemia Patients: Do We Still Need Intravenous Cladribine?;Turkish Journal of Internal Medicine;2023-04-29